Wednesday, August 12, 2026
← Back to archivePolicy
Policy•KFF•Aug 11, 2026
The White House Takes Another Shot at Changing U.S. Childhood Vaccine Recommendations
background ▾
- •Executive Order aims to reduce routine childhood vaccine schedule from 13 to 7 vaccines and targets from 17 to 11 diseases, with explicit directive to split MMR into separate shots—a policy contradicted by international evidence and U.S. manufacturer licensing.
- •The creation of a federal HHS Task Force (comprised of government officials, not external experts) could circumvent traditional CDC/ACIP authority over vaccine recommendations, representing a significant shift in vaccine policy governance.
- •Implementation faces substantial headwinds: 30 states plus DC have already decoupled from federal vaccine recommendations; private insurers have committed to maintaining current coverage through end of 2027; and splitting MMR vaccines could trigger measles/mumps/rubella resurgence as historical precedent from Japan demonstrates.
MMR vaccineMeasles vaccineMumps vaccine
→ Read original articlePolicy•STAT News•Aug 12, 2026
Opinion: Climate change is making people with chronic illness even sicker
background ▾
- •Climate-related environmental stressors (wildfire smoke, heat, floods, disease vectors) are documented to worsen chronic disease outcomes and may impair immune function, potentially creating new patient populations requiring therapeutic intervention
Policy•STAT News•Aug 11, 2026
Medicaid will stop paying for some gender-affirming care for transgender minors
background ▾
- •Federal Medicaid/CHIP coverage for gender-affirming surgeries eliminated immediately; hormone treatment phase-out effective April 2027, with mental health coverage preserved
- •Policy faces likely legal challenge from LGBTQ+ advocates and aligns with existing state-level bans (27 states) but contradicts positions of major medical organizations including AMA
- •Monitor: Federal court rulings on constitutional challenges, implementation details from CMS, and potential legislative responses
Policy•Endpoints News•Aug 11, 2026
AbbVie, Novartis and Bristol Myers Squibb file 340B lawsuits in Illinois
background ▾
- •Three major pharmaceutical companies are simultaneously litigating against 340B program rules in Illinois, signaling coordinated industry pressure to challenge the program's current structure
- •This represents a significant escalation in manufacturer legal challenges to 340B, which has become a major flashpoint between pharma and healthcare providers over drug pricing and program administration
- •Watch for the specific legal claims filed, potential consolidation of cases, and whether other manufacturers join or file similar suits in other jurisdictions
AbbVieNovartisBristol Myers Squibb
→ Read original articlePolicy•Endpoints News•Aug 11, 2026
Two health insurers give an AI reality check
background ▾
- •Health insurers are moderating AI investment expectations after years of high-profile commitments, signaling slower-than-anticipated ROI and implementation challenges
- •This skepticism may reshape how payers deploy AI for pharmacy benefits management and prior authorization, affecting drug access and manufacturer-payer negotiations
UnitedHealth Group
→ Read original articleMarket Access
Market Access•Endpoints News•Aug 11, 2026
Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think so
background ▾
- •Exelixis faces allegations of product-hopping via minor formulation changes to extend patent protection on a major revenue driver
- •The practice, if substantiated, raises questions about regulatory oversight of incremental modifications and anti-competitive strategies in pharmaceutical development
- •Watch for regulatory agency response, potential legal challenges, and impact on Exelixis's patent exclusivity timeline and generic competition
Exelixis
→ Read original articleMarket Access•Fierce Biotech•Aug 11, 2026
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
background ▾
- •Alvelestat represents a meaningful commercial opportunity in AATD-LD, a small rare disease market with limited treatment options (only one FDA-approved therapy) and high unmet need for oral alternatives to weekly IV infusions.
- •The $475M deal structure reflects confidence in phase 2 efficacy data but substantial execution risk tied to phase 3 success; Sentynl's option-based structure limits downside exposure while Mereo retains global development control.
- •Monitor phase 3 trial enrollment and interim efficacy readouts; regulatory approval timing will determine whether alvelestat can capture meaningful market share from the entrenched IV plasma therapy standard of care.
Sentynl TherapeuticsZydus LifesciencesMereo BioPharmaalvelestatNulibryZokinvy
→ Read original articleMarket Access•Fierce Biotech•Aug 11, 2026
Amgen lays groundwork for new R&D center in Hyderabad
background ▾
- •Amgen is committing to significant R&D infrastructure in India's Genome Valley, placing it among major pharmas expanding in the region
- •The center will integrate experimental science with AI and data capabilities across discovery, metabolism, and precision medicine—indicating emphasis on technology-enabled drug development
- •Investment cost and job creation targets were not disclosed, limiting visibility into scale and commitment level
AmgenEli LillyNovartis
→ Read original articleMarket Access•Fierce Biotech•Aug 11, 2026
Abbott teams with Google Health on AI-powered health insights app
background ▾
- •Abbott's Lingo consumer CGM now integrates with Google Health's AI platform to deliver personalized metabolic insights at consumer scale, leveraging Google's machine learning capabilities to drive user engagement and health behavior change.
- •The partnership includes a major real-world metabolic health study combining CGM, wearable, laboratory, and survey data to identify prediabetes risk and inform lifestyle interventions—outcomes data from this study could strengthen market positioning and inform future digital health innovation.
- •Monitor real-world adoption rates and clinical validation results from the metabolic health study, as well as competitive responses from other CGM manufacturers and digital health platforms seeking similar AI-enabled partnerships.
AbbottGoogle HealthLingo
→ Read original articleMarket Access•Endpoints News•Aug 11, 2026
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
background ▾
- •Eli Lilly deployed $2 billion in upfront payments for vaccine biotech acquisitions, indicating prioritization of vaccine development as core growth driver
- •Infinimmune raised $75 million in financing alongside other emerging biotech funding activity, suggesting healthy investor appetite for immunology/vaccine space despite broader biotech funding headwinds
- •Monitor for official announcements detailing the acquired vaccine targets and clinical stages, as well as Lilly's integration timeline and R&D strategy for these assets
Eli LillyInfinimmuneTenax Therapeutics
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 12, 2026
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
background ▾
- •Triple combination of leronlimab + bNabs + antiretroviral therapy achieved apparent HIV cure in 8/8 treated infant macaques with sustained viral freedom for one year post-treatment
- •Leronlimab alone or in dual combinations failed to prevent viral reservoir establishment, indicating synergy is essential for the cure approach
- •Critical unknowns persist about adult efficacy, post-infection treatment window, and mechanism—limiting immediate path to human trials despite promising macaque data
CytoDynGSK ViiV HealthcarePfizerleronlimabSelzentry
→ Read original articleClinical Trials•STAT News•Aug 11, 2026
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
background ▾
- •Statin discontinuation in healthy adults over 75 with no cardiovascular history showed non-inferiority to continued therapy over 3 years with no mortality or major cardiovascular event differences
- •Results conflict with larger non-randomized cohort studies from Denmark and Italy showing ~30% higher cardiovascular risk after statin discontinuation in older adults, highlighting the importance of study design and population selection
- •Further research needed in longer timeframes and higher-risk populations; experts recommend individualized patient discussion rather than wholesale statin de-prescription in older adults
statins
→ Read original articleClinical Trials•Fierce Biotech•Aug 11, 2026
Epicrispr raises $90M to rewrite treatment of rare muscle disease
background ▾
- •Interim Phase 1/2 data in FSHD shows measurable lean muscle mass gains (0.5–1.3 lbs) six months after single EPI-321 infusion in three patients, providing early clinical validation for epigenetic DUX4 suppression strategy.
- •Epicrispr's $90M Series C capitalizes on this readout to compete in an increasingly crowded FSHD market, now including Phase 3 asset (Novartis/Avidity) and multiple Phase 1/2–2 programs (Sarepta, Scholar Rock).
- •Watch for Phase 2 expansion data on muscle strength/function (not just mass), durability of response, and whether epigenetic approach offers durability or safety advantages over competing modalities in FSHD race.
Epicrispr BiotechnologiesSanofi VenturesOctagon CapitalEPI-321delpacibart braxlosiran
→ Read original articleClinical Trials•Endpoints News•Aug 11, 2026
Epicrispr secures $90M after early data on epigenetic FSHD treatment
background ▾
- •Epicrispr raised $90M Series C on back of early FSHD data using an epigenetic modulation approach, signaling investor confidence in a potentially differentiated mechanism
- •The epigenetic strategy represents a distinct therapeutic approach from conventional CRISPR gene editing, suggesting potential advantages in treating muscular dystrophy
- •Clinical advancement timeline and head-to-head efficacy data versus other FSHD candidates will be critical inflection points for the program's commercial viability
Epicrispr Biotechnologies
→ Read original articleClinical Trials•Fierce Biotech•Aug 11, 2026
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
background ▾
- •Aura is narrowing its pipeline from multi-indication development to a focused ocular oncology strategy, de-prioritizing NMIBC despite 'encouraging' early data to preserve future strategic optionality.
- •Phase 3 enrollment complete in early choroidal melanoma with topline data expected H2 2025—the critical inflection point for the company's viability.
- •Watch for: phase 3 efficacy/safety readout in choroidal melanoma; any partnership or acquisition discussions given 'strategic optionality' language; impact of knowledge loss from 20% headcount reduction on trial execution.
Aura Biosciencesbelzupacap sarotalocan
→ Read original article